ELAB vs. CLNN, DRRX, CASI, NBRV, CARM, KRON, OCUP, AADI, LEXX, and EYEN
Should you be buying Elevai Labs stock or one of its competitors? The main competitors of Elevai Labs include Clene (CLNN), DURECT (DRRX), CASI Pharmaceuticals (CASI), Nabriva Therapeutics (NBRV), Carisma Therapeutics (CARM), Kronos Bio (KRON), Ocuphire Pharma (OCUP), Aadi Bioscience (AADI), Lexaria Bioscience (LEXX), and Eyenovia (EYEN). These companies are all part of the "pharmaceutical preparations" industry.
Clene (NASDAQ:CLNN) and Elevai Labs (NASDAQ:ELAB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, community ranking, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.
Clene received 60 more outperform votes than Elevai Labs when rated by MarketBeat users.
Elevai Labs has a net margin of -211.25% compared to Elevai Labs' net margin of -7,873.23%. Elevai Labs' return on equity of -224.28% beat Clene's return on equity.
23.3% of Clene shares are owned by institutional investors. Comparatively, 22.2% of Elevai Labs shares are owned by institutional investors. 25.1% of Clene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Elevai Labs had 2 more articles in the media than Clene. MarketBeat recorded 2 mentions for Elevai Labs and 0 mentions for Clene. Elevai Labs' average media sentiment score of 0.00 beat Clene's score of -0.36 indicating that Clene is being referred to more favorably in the media.
Clene presently has a consensus target price of $6.50, suggesting a potential upside of 1,648.25%. Given Elevai Labs' higher probable upside, analysts plainly believe Clene is more favorable than Elevai Labs.
Elevai Labs has higher revenue and earnings than Clene. Elevai Labs is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.
Summary
Clene beats Elevai Labs on 10 of the 15 factors compared between the two stocks.
Get Elevai Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elevai Labs Competitors List
Related Companies and Tools
